Earlier translation of evidence into public subsidy may prevent morbidity and mortality: An example using statins in diabetics with normal cholesterol levels

Australian and New Zealand Journal of Public Health

Volumn 36, Issue 5, 2012, Pages 435-440

  Page, Michael M ^a   Sanfilippo, Frank M ^a   Geelhoed, Elizabeth A ^a   Briffa, Tom G ^a   Hobbs, Michael S T ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Coronary disease; Diabetes mellitus; Epidemiology methods; Hydroxymethylglutaryl CoA reductase inhibitors; Pharmaceutical Benefits Scheme; Pharmacoepidemiology; Population estimates; Stroke

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; AUSTRALIA; BLOOD; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; EVIDENCE BASED MEDICINE; FEMALE; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; TIME;

AGED; AUSTRALIA; CHOLESTEROL; CONFIDENCE INTERVALS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; MORBIDITY; POPULATION SURVEILLANCE; PREVALENCE; RISK FACTORS; STROKE; TIME FACTORS;

EID: 84867030268     PISSN: 13260200     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1753-6405.2012.00887.x     Document Type: Article

References (31)

1. Martin MJ, Browner WS, Hulley SB, et al. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361 662 men. Lancet. 1986;328:933-6.
2. Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton L, Lazo J, Parker K, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York (NY): McGraw Hill; 2006.
3. Cheung BM, Lauder IJ, Lau C-P, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57:640-51.
4. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-7.
5. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
7. Department of Health and Ageing. PBS Publication Archives [Internet]. Canberra (AUST): Commonwealth of Australia; 2009 [cited 2009 Apr 5]. Available from: http://www.pbs.gov.au/info/publication/schedule/archive
8. Hamilton-Craig I. The Heart Protection Study: implications for clinical practice [editorial]. Med J Aust. 2002;177:404-5.
9. National Prescribing Service. Revised PBS criteria for lipid-modifying drugs. NPS RADAR. 2007;April:1-6.
10. Australian Bureau of Statistics. 4364.0 - National Health Survey: Summary of Results (2001). Canberra (AUST): ABS; 2002.
11. Australian Bureau of Statistics. 3201.0 - Population by age and sex (June 1997 to June 2002). Canberra (AUST): ABS; 2003.
12. Hobbs MS, Knuiman MW, Briffa T, et al. Plasma cholesterol levels continue to decline despite the rising prevalence of obesity: population trends in Perth, Western Australia, 1980-1999. Eur J Cardiovasc Prev Rehabil. 2008;15:319-24.
13. UKPDS Risk Engine: risk calculators [computer program]. Version 2.01. Oxford (UK): Oxford University, Diabetes Trials Unit; 2009.
14. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes. Clin Sci. 2001;101:671-9.
15. Oehlert GW. A note on the delta method. Am Stat. 1992;46:27-9.
16. Department of Health and Ageing. MBS Online [Internet]. Canberra (AUST): Commonwealth of Australia; 2009 [cited 2012 Mar 23]. Available from: http:// www.mbsonline.gov.au
17. Ioannides-Demos LL, Makarounas-Kirchmann K, Ashton E, et al. Cost of myocardial infarction to the Australian community; a prospective, multicentre study. Clin Drug Investig. 2010;30:533-43.
18. Department of Health and Ageing. Data Collections: Round 9 (2004-2005) Cost Report Version 5.0 [Internet]. Canberra (AUST): Commonwealth of Australia; 2006 [cited 2011 Feb 10]. Available from: http://health.gov.au/internet/main/ publishing.nsf/Content/+Round-9-cost-reports
19. Dewey HM, Thrift AG, Mihalopoulos C, et al. Cost of stroke in Australia from a societal perspective. Stroke. 2001;32:2409-16.
20. Hurley SF. Short-term impact of smoking cessation on myocardial infarction and stroke hospitalisations and costs in Australia. Med J Aust. 2005;183:13-17.
21. Australian Institute of Health and Welfare. Health Expenditure Australia 2007-08. Cat. no. HWE 46. Canberra (AUST): AIHW; 2009.
22. Medicare Australia. Pharmaceutical Benefits Schedule Item Statistics Reports [Internet]. Canberra (AUST): Commonwealth of Australia; 2011 [cited 2011 Oct 30]. Available from: https://www.medicareaustralia.gov.au/statistics/pbs- item. shtml
23. Begg S, Vos T, Barker B, et al. The Burden of Disease and Injury in Australia 2003. PHE 82. Canberra (AUST): Australian Institute of Health and Welfare; 2007.
24. Krum H, Meehan A, Varigos J, et al. Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? A multicentre study. Med J Aust. 2006;185:191-4.
25. Thomas MC, Nestel PJ. Management of dyslipidaemia in patients with type 2 diabetes in Australian primary care. Med J Aust. 2007;186:128-30.
26. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164:208-11.
27. Knox SA, Harrison CM, Britt HC, Henderson JV. Estimating prevalence of common chronic morbidities in Australia. Med J Aust. 2008;189:66-70.
28. Simons LA, Sullivan DR. Lipid-modifying drugs. Med J Aust. 2005;182:286-9.
29. Haynes B, Haines A. Barriers and bridges to evidence based clinical practice. BMJ. 1998;317:273.
30. Snell G, Kotsimbos T, Williams TJ. Lung transplantation in Australia: barriers to translating new evidence into clinical practice. Med J Aust. 2006;184:428-9.
31. Beggs S. Australian report on pediatric medication issues. Paediatr Drugs. 2009;11:38-40.